Key result
Neither eGFR estimated from serum creatinine nor from serum cystatin C predicted future change in kidney function over a 2-year period, with c-statistics of 0.495 and 0.497 respectively.
Why the study?
Monitoring is key to chronic kidney disease management in primary care, but evidence regarding the best monitoring method is limited.
Does eGFR derived from serum cystatin C improve prediction of renal function decline compared to serum creatinine in primary care patients with reduced eGFR?
Cohort (n=750)
Yes
Does eGFR derived from serum cystatin C improve prediction of renal function decline compared to serum creatinine in primary care patients with reduced eGFR?
Answers are grounded in this paper and cite their sources.
Neither serum creatinine nor serum cystatin C-derived eGFR effectively predicted future change in kidney function over 2 years in primary care patients with mildly reduced eGFR, supporting current guidelines that do not recommend routine replacement of creatinine with cystatin C.
Background Monitoring is the mainstay of chronic kidney disease management in primary care; however, there is little evidence about the best way to do this. Aim To compare the effectiveness of estimated glomerular filtration rate (eGFR) derived from serum creatinine and serum cystatin C to predict renal function decline among those with a recent eGFR of 30–89 ml/min/1.73 m 2 . Design and setting Observational cohort study in UK primary care. Method Serum creatinine and serum cystatin C were both measured at seven study visits over 2 years in 750 patients aged ≥18 years with an eGFR of 30–89 ml/min/1.73 m 2 within the previous year. The primary outcome was change in eGFR derived from serum creatinine or serum cystatin C between 6 and 24 months. Results Average change in eGFR was 0.51 ml/min/1.73 m 2 /year when estimated by serum creatinine and −2.35 ml/min/1.73 m 2 /year when estimated by serum cystatin C. The c-statistic for predicting renal decline using serum creatininederived eGFR was 0.495 (95% confidence interval [CI] = 0.471 to 0.519). The equivalent c-statistic using serum cystatin C-derived eGFR was 0.497 (95% CI = 0.468 to 0.525). Similar results were obtained when restricting analyses to those aged ≥75 or <75 years, or with eGFR ≥60 ml/min/1.73 m 2 . In those with eGFR <60 ml/min/1.73 m 2 , serum cystatin C-derived eGFR was more predictive than serum creatinine-derived eGFR for future decline in kidney function. Conclusion In the primary analysis neither eGFR estimated from serum creatinine nor from serum cystatin C predicted future change in kidney function, partly due to small changes during 2 years. In some secondary analyses there was a suggestion that serum cystatin C was a more useful biomarker to estimate eGFR, especially in those with a baseline eGFR <60 ml/min/1.73 m 2 .
No takes yet. Share an insight, caveat, or question.
Fleming et al. (2021) conducted a cohort in Reduced eGFR (CKD stages 2 and 3) (n=750). Serum cystatin C-derived eGFR vs. Serum creatinine-derived eGFR was evaluated on Change in eGFR between 6 and 24 months (c-statistic for predicting renal decline) (Difference -0.00157, 95% CI -0.0358 to 0.0273). Neither eGFR estimated from serum creatinine nor from serum cystatin C predicted future change in kidney function over a 2-year period, with c-statistics of 0.495 and 0.497 respectively.
Synapse has enriched 10 related papers. Consider them for comparative context: